BioNTech’s gotistobart beat docetaxel after checkpoint therapy failed. What makes its CTLA-4 design different?
BioNTech and OncoC4 have reported median overall survival of 18.5 months with gotistobart versus 10 months with docetaxel in previously treated squamous non-small cell lung cancer. The result revives interest in CTLA-4 immunotherapy after PD-1 or PD-L1 treatment failure, but it came from the non-pivotal first stage of PRESERVE-003, leaving a much larger global cohort
